Cargando…

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison

BACKGROUND: Plaque psoriasis has significant impact on patients’ quality of life. Topical therapy is considered the treatment mainstay for mild‐to‐moderate disease according to guidelines. Calcipotriol/betamethasone dipropionate (Cal/BD) [0.005%/0.05%] aerosol foam is indicated for psoriasis vulgari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bewley, A.P., Shear, N.H., Calzavara‐Pinton, P.G., Hansen, J.B., Nyeland, M.E., Signorovitch, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Psoriasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766948/ https://www.ncbi.nlm.nih.gov/pubmed/30472749 http://dx.doi.org/10.1111/jdv.15369

Ejemplares similares

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study
por: Paul, C., et al.
Publicado: (2016)

Non‐invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator‐initiated, phase IV, unicentric, open, randomized clinical trial
por: Yélamos, O., et al.
Publicado: (2020)

Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open‐label trial
por: Seyger, M., et al.
Publicado: (2020)

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008)

Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
por: Koo, John, et al.
Publicado: (2016)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
por: Reich, K., et al.
Publicado: (2016)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019)

Real-World Experience Using Topical Therapy—Calcipotriol and Betamethasone Dipropionate Foam in Adults with Beyond-Mild Psoriasis
por: Aschoff, Roland, et al.
Publicado: (2021)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
por: Thaçi, D., et al.
Publicado: (2016)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients
por: Aschoff, Roland, et al.
Publicado: (2021)

Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analysis of PSO‐LONG
por: Jalili, A., et al.
Publicado: (2021)

Efficacy and Safety of Calcipotriol/Betamethasone Dipropionate Ointment for the Treatment of Trachyonychia: An Open-Label Study
por: Park, Jung-Min, et al.
Publicado: (2015)

Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
por: Rudnicka, Lidia, et al.
Publicado: (2021)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Long‐term real‐life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single‐centre, retrospective, observational study
por: Dickel, H., et al.
Publicado: (2018)

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
por: Pinter, Andreas, et al.
Publicado: (2018)

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis
por: Queille-Roussel, Catherine, et al.
Publicado: (2016)

Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence
por: Takahashi, Hidetoshi, et al.
Publicado: (2020)

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
por: Seneschal, J., et al.
Publicado: (2020)

Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians
por: van Ee, I., et al.
Publicado: (2021)

Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris
por: Kontochristopoulos, George, et al.
Publicado: (2016)

Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris
por: Queille-Roussel, Catherine, et al.
Publicado: (2015)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis
por: Stein Gold, Linda, et al.
Publicado: (2016)

Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model
por: Satake, Kyosuke, et al.
Publicado: (2019)

Efficacy of calcipotriol plus betamethasone dipropionate foam on psoriatic skin lesions beyond human eyes: An observational study
por: Anna, Campanati, et al.
Publicado: (2022)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
por: Mease, P.J., et al.
Publicado: (2019)

Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach
por: De Simone, Clara, et al.
Publicado: (2022)

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
por: Colombo, Giorgio L, et al.
Publicado: (2012)

Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
por: Gooderham, M, et al.
Publicado: (2014)

The Effect of the Long-Term Calcipotriol/Betamethasone Dipropionate Local Therapy on Tissue Resident Memory Cells Markers in Psoriatic Eruptions
por: Kasprowicz-Furmańczyk, Marta, et al.
Publicado: (2022)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency
por: Tada, Y., et al.
Publicado: (2021)

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination
por: Jalili, Ahmad, et al.
Publicado: (2022)

Kinetics of Thermal Degradation of Betamethasone Valerate and Betamethasone Dipropionate in Different Media
por: Khattak, S. U. R., et al.
Publicado: (2012)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)
por: Callis Duffin, K., et al.
Publicado: (2016)

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study
por: Cai, L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k69a2ejnodmu3ngmp042bmp9hs